Literature DB >> 8456559

Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases.

N Ronda1, V Hurez, M D Kazatchkine.   

Abstract

The proven beneficial effect of intravenous immunoglobulins (IVIg) in certain autoimmune disorders has led to the development of clinical trials in other autoimmune and systemic inflammatory diseases. In parallel, experimental studies are being carried out to better understand the mechanisms of action of IVIg. In this review, we discuss the clinical use of IVIg in autoimmune disorder and the possible mechanisms by which IVIg may be effective in the various diseases. A better understanding of the mechanisms of action of IVIg in autoimmune disease will allow optimization of their use as a therapeutic alternative to conventional immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456559     DOI: 10.1111/j.1423-0410.1993.tb02521.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  10 in total

Review 1.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 2.  Intravenous immunoglobulin treatment in neurological diseases.

Authors:  A Otten; M Vermeulen; P M Bossuyt; A Otten
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

3.  Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis.

Authors:  M Galeazzi; A M Bellucci; C R Girardelli; R Bono; O De Pita; P Puddu
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

Review 4.  Treatment of autoimmune diseases with normal immunoglobulin through manipulation of the idiotypic network.

Authors:  N Ronda; S V Kaveri; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

Review 5.  Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin.

Authors:  S C Jordan; M Toyoda
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.

Authors:  J Wada; N Shintani; K Kikutani; T Nakae; T Yamauchi; K Takechi
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

7.  Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal:  Int J Exp Pathol       Date:  2004-12       Impact factor: 1.925

8.  Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation.

Authors:  J C Magee; B H Collins; R C Harland; B J Lindman; R R Bollinger; M M Frank; J L Platt
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

9.  Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases.

Authors:  A Sansome; V Dubowitz
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

10.  The effects of immunotherapy with intravenous immunoglobulins versus no intervention, placebo, or usual care in patients with recurrent miscarriages: a protocol for a systematic review with meta-analyses, trial sequential analyses, and individual patient data meta-analyses of randomised clinical trials.

Authors:  Pia Egerup; Jane Lindschou; Christian Gluud; Ole Bjarne Christiansen
Journal:  Syst Rev       Date:  2014-08-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.